InMed Pharmaceuticals Says INM-901 Demonstrates Unique Pharmacological Effects In Alzheimer's Disease In Preclinical Proof-Of-Concept Studies
Portfolio Pulse from Benzinga Newsdesk
InMed Pharmaceuticals has announced that its drug INM-901 has shown unique pharmacological effects in Alzheimer's disease in preclinical proof-of-concept studies.
October 24, 2023 | 11:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InMed Pharmaceuticals' INM-901 has shown promising results in preclinical studies for Alzheimer's disease, which could potentially lead to a breakthrough in the treatment of this disease.
The announcement of positive preclinical results for INM-901 could potentially boost InMed Pharmaceuticals' stock in the short term as it indicates progress in the development of the drug. This could attract investors who are interested in the pharmaceutical sector and specifically in treatments for Alzheimer's disease.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100